Literature DB >> 10736404

Agents for treatment of invasive fungal infections.

B Luna1, R H Drew, J R Perfect.   

Abstract

The incidence of fungal infections continues to rise as the population of immunocompromised individuals increases. Despite the enlarging numbers of infections, there are only a few antifungal agents for treatment of deep-seated, invasive infections. These agents include amphotericin B, flucytosine, terbinafine, and several azoles. Progress has been made in understanding the role of these agents in a variety of infections and this article examines in detail these agents and their prophylactic, empiric, and therapeutic uses in invasive mycoses. This article focuses on general concepts of antifungal therapies and provides a detailed review of each antifungal agent available for treatment of deep-seated mycoses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10736404     DOI: 10.1016/s0030-6665(00)80005-5

Source DB:  PubMed          Journal:  Otolaryngol Clin North Am        ISSN: 0030-6665            Impact factor:   3.346


  7 in total

Review 1.  Pharmacokinetics of antifungal agents in children.

Authors:  Kevin Watt; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  Early Hum Dev       Date:  2011-02-01       Impact factor: 2.079

2.  [Classification of etiologic agents in fungal sinusitis by immunohistochemistry, histology and culture].

Authors:  K Wölke; G Jautzke; O Kaschke; B Seefeld
Journal:  Pathologe       Date:  2004-09       Impact factor: 1.011

Review 3.  Advances in the treatment of invasive neonatal candidiasis.

Authors:  Lorena Botero-Calderon; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  Expert Opin Pharmacother       Date:  2015-04-05       Impact factor: 4.103

4.  Mucormycosis of nose and paranasal sinuses with orbital complication in young diabetic.

Authors:  R K Mundra; Yamini Gupta
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2009-01-28

Review 5.  Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.

Authors:  Chris Stockmann; Jonathan E Constance; Jessica K Roberts; Jared Olson; Elizabeth H Doby; Krow Ampofo; Justin Stiers; Michael G Spigarelli; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2014-05       Impact factor: 6.447

Review 6.  Pediatric antifungal agents.

Authors:  Michael Cohen-Wolkowiez; Cassandra Moran; Daniel K Benjamin; Phillip B Smith
Journal:  Curr Opin Infect Dis       Date:  2009-12       Impact factor: 4.915

Review 7.  Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications.

Authors:  Julie Autmizguine; Jeffrey T Guptill; Michael Cohen-Wolkowiez; Daniel K Benjamin; Edmund V Capparelli
Journal:  Drugs       Date:  2014-06       Impact factor: 11.431

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.